News

Chandra Briggman among the Virginia Best Black Business Leaders

Richmond, VA /Virginia Business/ – Black History Month traces its origins to an annual weeklong observance started in 1926 by historian and scholar Carter G. Woodson, a Virginia native. And since then, the February celebration of Black history makers and events has been intertwined with commemorating successful business icons like fellow Virginia-born greats Maggie Walker and Booker T. Washington.

With this in mind, Virginia Business presents our 2023 Virginia Black Business Leaders Awards, recognizing a reader-nominated group of some of the state’s most accomplished Black executives. On this inaugural list are 17 leaders, chosen from 108 nominated executives in finance, federal contracting, higher education, law, technology and other sectors. Our editorial team selected the 17 winners, scoring nominations based on factors including overall professional achievement, community impact and mentoring.

…

Chandra Briggman, President and CEO, Activation Capital, Richmond – The leader since 2020 of a Richmond-based innovation incubator that includes a biotech park, startup development and a newly invigorate

d cluster accelerator for pharmaceutical research and manufacturing, Briggman is off to a fast start. Growing up in a town of 2,000 in rural South Carolina, she was inspired by her parents to pursue innovation.

“Neither one of my parents had the opportunity to go to college,” Briggman says. “I consider them two of the smartest people I know. They were doers and experimenters, and that foundation was important.”

After college, Briggman worked for the U.S. Postal Service, where she learned about the intersection of service and technology, then for a Boston nonprofit promoting entrepreneurship. At Activation Capital, her role is “to manufacture entrepreneurs at scale,” she says — including recently landing a $53 million federal grant to expand manufacturing and development of pharmaceuticals in the Richmond region.

Read more here.

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …